Overall Survival Results From Monaleesa-2: Endocrine Therapy And Ribociclib In Hr Positive And H...

Overall survival results from MONALEESA-2: Endocrine therapy and ribociclib in HR positive and H...

Overall survival results from MONALEESA-3 study on ribociclib plus fulvestrant in advanced breas...

GS2-00: "Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2..."

San Antonio Breast Cancer Symposium

Final overall survival analysis of MONARCH 1

MONALEESA-2: improved OS seen in HR+ advanced breast cancer treated with ribociclib + letrozole

Dr. Hortobagyi on MONALEESA-2 Trial Results in Breast Cancer

MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BC

Ribociclib plus endocrine therapy boosts survival of HR+/HER2- breast cancer

MDedge: news and insights for busy physicians

MONALEESA-2: ribociclib + letrozole in pts with de novo metastatic disease and late recurrence

Safety and efficacy of ribociclib and letrozole in advanced breast cancer – the MONALEESA-2 trial

Evolving Perspectives on HR-Positive Metastatic Breast Cancer: Current Understanding and New Insi...

Evolving Landscape of HR-Positive Metastatic Breast Cancer: A Year in Review

QOL in MONALEESA-2, 3, and 7

Updated Results of the MONALEESA-2 Trial in HR+/HER2- Breast Cancer

Targeted Oncology

MONARCH 2: Overall survival results from abermaciclib plus fulvestrant in HR+ HER2- advanced bre...

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine ther...

CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-nega...

MONALEESA-7: Ribociclib in Premenopausal Women With mBC

Overall survival (OS) results of the Phase III MONALEESA-3 trial

Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast...